Related Experiment Videos
Evaluation of endpoints in hypertension: blood pressure
1University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow, UK.
Insights
Antihypertensive therapy effectively reduces cardiovascular and cerebrovascular events by lowering blood pressure. Achieving consistent, normotensive blood pressure levels is crucial for optimal patient outcomes in hypertension management.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Meta-analyses of randomized trials confirm antihypertensive therapy's efficacy in reducing cerebrovascular and cardiac events.
- While diuretics and beta-blockers were common, treatment benefits appear linked to blood pressure reduction itself, not specific drug classes.
- Blood pressure is the sole validated surrogate marker for cardiovascular outcomes.
Purpose of the Study:
- To evaluate the effectiveness of antihypertensive therapy in managing cardiovascular and cerebrovascular events.
- To determine if blood pressure reduction per se, rather than specific drug classes, is responsible for therapeutic benefits.
- To assess the consistency and adequacy of blood pressure control in routine clinical practice.
Main Methods:
- Review of meta-analyses from randomized outcome trials on antihypertensive therapy.
- Analysis of epidemiological evidence regarding blood pressure control strategies.
- Evaluation of routine clinical practice data for treated hypertensive patients.
Main Results:
- Antihypertensive therapy significantly reduces cerebrovascular and cardiac events.
- The benefit of therapy is attributed to blood pressure reduction, irrespective of the drug class used.
- In clinical practice, treated hypertensives often do not achieve normotensive levels, with inconsistent 24-hour control.
Conclusions:
- Blood pressure reduction is the key factor in preventing cardiovascular and cerebrovascular events.
- Current clinical practice shows inadequate and inconsistent blood pressure control in hypertensive patients.
- Treatment strategies should aim for smooth and consistent blood pressure reduction to normotensive levels.
Abstract:
The benefits of antihypertensive therapy in reducing both cerebrovascular and cardiac events have been clearly demonstrated in the meta-analysis of randomised outcome trials. Whilst the use of diuretics and beta-blockers have tended to predominate in these trials, other agents were also included and thus it is reasonable to suggest that the benefit of treatment is not attributable to any particular class of agent but rather to a reduction in blood pressure per se. It may therefore, be reasonably argued that blood pressure itself is the only validated surrogate marker of cardiovascular outcome. In routine clinical practice evaluation has indicated that in treated hypertensives not only is blood pressure not lowered to normotensive levels but also that control of pressure was not consistent over a 24 hour period. Finally epidemiological evidence suggests that blood pressure control should be based upon treatment strategies that lower blood pressure to normotensive levels in a smooth and consistent fashion.